Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients

Anna Catania, Mariagrazia Cutuli, Letizia Garofalo, Lorena Airaghi, Franco Valenza, James M. Lipton, Luciano Gattinoni

Research output: Contribution to journalArticle

Abstract

Objectives: The aim of this research was to investigate endogenous concentrations and anti-cytokine effects of the anti-inflammatory peptide α- melanocyte stimulating hormone (α-MSH) in patients with systemic inflammation. The objectives were to determine the following: changes over time of plasma α-MSH and relationship with patient outcome, correlation between plasma α-MSH and tumor necrosis factor (TNF)-α plasma concentration and production in whole blood samples, and influences of α-MSH on production of TNF-α and interleukin (IL)-1β in whole blood samples stimulated with lipopolysaccharide (LPS). Design: Prospective, nonrandomized, clinical study. Setting: Intensive care unit of a university hospital. Patients: A total of 21 patients with sepsis syndrome/septic shock and an equal number of healthy volunteers. Interventions: Circulating α-MSH and TNF-α concentrations and TNF-α production in supernatants of LPS (1 ng/mL)-stimulated whole blood were measured repeatedly. To determine whether α-MSH can modulate production of TNF-α and IL-1 β, these cytokines were measured in whole blood samples stimulated with LPS (1 ng/mL) in the presence or absence of concentrations of the peptide. Measurements and Main Results: Plasma α-MSH was low in early samples and gradually increased in patients who recovered but not in those who died. There was a negative correlation between plasma concentrations of α-MSH and TNF-α. In blood samples taken at early phases of sepsis syndrome, production of TNF-α was reduced relative to control values; such production increased in patients who recovered but not in those who died. Addition of α-MSH to LPS-stimulated whole blood samples inhibited production of TNF-α and IL-1β in a concentration-dependent manner. Conclusions: In patients with systemic inflammation, there are substantial changes over time in plasma concentrations of α-MSH that are reduced in early phases of the disease. Reduction of this endogenous modulator of inflammation could be detrimental to the host. Addition of α-MSH to LPS-stimulated blood samples reduces production of cytokines involved in development of septic syndrome. This inhibition by α-MSH, a peptide that is beneficial in treatment of experimental models of sepsis, might therefore be useful to treat sepsis syndrome in humans.

Original languageEnglish
Pages (from-to)1403-1407
Number of pages5
JournalCritical Care Medicine
Volume28
Issue number5
Publication statusPublished - 2000

Fingerprint

Melanocyte-Stimulating Hormones
Cytokines
Tumor Necrosis Factor-alpha
Lipopolysaccharides
Systemic Inflammatory Response Syndrome
Interleukin-1
Inflammation
Peptides
Septic Shock
Intensive Care Units
Sepsis
Healthy Volunteers

Keywords

  • α-melanocyte stimulating hormone
  • Cytokine production
  • Interleukin-1
  • Lipopolysaccharide
  • Sepsis syndrome
  • Septic shock
  • Systemic inflammation
  • Tumor necrosis factor-α
  • Whole blood

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients. / Catania, Anna; Cutuli, Mariagrazia; Garofalo, Letizia; Airaghi, Lorena; Valenza, Franco; Lipton, James M.; Gattinoni, Luciano.

In: Critical Care Medicine, Vol. 28, No. 5, 2000, p. 1403-1407.

Research output: Contribution to journalArticle

Catania, A, Cutuli, M, Garofalo, L, Airaghi, L, Valenza, F, Lipton, JM & Gattinoni, L 2000, 'Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients', Critical Care Medicine, vol. 28, no. 5, pp. 1403-1407.
Catania, Anna ; Cutuli, Mariagrazia ; Garofalo, Letizia ; Airaghi, Lorena ; Valenza, Franco ; Lipton, James M. ; Gattinoni, Luciano. / Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients. In: Critical Care Medicine. 2000 ; Vol. 28, No. 5. pp. 1403-1407.
@article{5a61e56e32854d6eb40e8ebeb7055b9a,
title = "Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients",
abstract = "Objectives: The aim of this research was to investigate endogenous concentrations and anti-cytokine effects of the anti-inflammatory peptide α- melanocyte stimulating hormone (α-MSH) in patients with systemic inflammation. The objectives were to determine the following: changes over time of plasma α-MSH and relationship with patient outcome, correlation between plasma α-MSH and tumor necrosis factor (TNF)-α plasma concentration and production in whole blood samples, and influences of α-MSH on production of TNF-α and interleukin (IL)-1β in whole blood samples stimulated with lipopolysaccharide (LPS). Design: Prospective, nonrandomized, clinical study. Setting: Intensive care unit of a university hospital. Patients: A total of 21 patients with sepsis syndrome/septic shock and an equal number of healthy volunteers. Interventions: Circulating α-MSH and TNF-α concentrations and TNF-α production in supernatants of LPS (1 ng/mL)-stimulated whole blood were measured repeatedly. To determine whether α-MSH can modulate production of TNF-α and IL-1 β, these cytokines were measured in whole blood samples stimulated with LPS (1 ng/mL) in the presence or absence of concentrations of the peptide. Measurements and Main Results: Plasma α-MSH was low in early samples and gradually increased in patients who recovered but not in those who died. There was a negative correlation between plasma concentrations of α-MSH and TNF-α. In blood samples taken at early phases of sepsis syndrome, production of TNF-α was reduced relative to control values; such production increased in patients who recovered but not in those who died. Addition of α-MSH to LPS-stimulated whole blood samples inhibited production of TNF-α and IL-1β in a concentration-dependent manner. Conclusions: In patients with systemic inflammation, there are substantial changes over time in plasma concentrations of α-MSH that are reduced in early phases of the disease. Reduction of this endogenous modulator of inflammation could be detrimental to the host. Addition of α-MSH to LPS-stimulated blood samples reduces production of cytokines involved in development of septic syndrome. This inhibition by α-MSH, a peptide that is beneficial in treatment of experimental models of sepsis, might therefore be useful to treat sepsis syndrome in humans.",
keywords = "α-melanocyte stimulating hormone, Cytokine production, Interleukin-1, Lipopolysaccharide, Sepsis syndrome, Septic shock, Systemic inflammation, Tumor necrosis factor-α, Whole blood",
author = "Anna Catania and Mariagrazia Cutuli and Letizia Garofalo and Lorena Airaghi and Franco Valenza and Lipton, {James M.} and Luciano Gattinoni",
year = "2000",
language = "English",
volume = "28",
pages = "1403--1407",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Plasma concentrations and anti-L-cytokine effects of α-melanocyte stimulating hormone in septic patients

AU - Catania, Anna

AU - Cutuli, Mariagrazia

AU - Garofalo, Letizia

AU - Airaghi, Lorena

AU - Valenza, Franco

AU - Lipton, James M.

AU - Gattinoni, Luciano

PY - 2000

Y1 - 2000

N2 - Objectives: The aim of this research was to investigate endogenous concentrations and anti-cytokine effects of the anti-inflammatory peptide α- melanocyte stimulating hormone (α-MSH) in patients with systemic inflammation. The objectives were to determine the following: changes over time of plasma α-MSH and relationship with patient outcome, correlation between plasma α-MSH and tumor necrosis factor (TNF)-α plasma concentration and production in whole blood samples, and influences of α-MSH on production of TNF-α and interleukin (IL)-1β in whole blood samples stimulated with lipopolysaccharide (LPS). Design: Prospective, nonrandomized, clinical study. Setting: Intensive care unit of a university hospital. Patients: A total of 21 patients with sepsis syndrome/septic shock and an equal number of healthy volunteers. Interventions: Circulating α-MSH and TNF-α concentrations and TNF-α production in supernatants of LPS (1 ng/mL)-stimulated whole blood were measured repeatedly. To determine whether α-MSH can modulate production of TNF-α and IL-1 β, these cytokines were measured in whole blood samples stimulated with LPS (1 ng/mL) in the presence or absence of concentrations of the peptide. Measurements and Main Results: Plasma α-MSH was low in early samples and gradually increased in patients who recovered but not in those who died. There was a negative correlation between plasma concentrations of α-MSH and TNF-α. In blood samples taken at early phases of sepsis syndrome, production of TNF-α was reduced relative to control values; such production increased in patients who recovered but not in those who died. Addition of α-MSH to LPS-stimulated whole blood samples inhibited production of TNF-α and IL-1β in a concentration-dependent manner. Conclusions: In patients with systemic inflammation, there are substantial changes over time in plasma concentrations of α-MSH that are reduced in early phases of the disease. Reduction of this endogenous modulator of inflammation could be detrimental to the host. Addition of α-MSH to LPS-stimulated blood samples reduces production of cytokines involved in development of septic syndrome. This inhibition by α-MSH, a peptide that is beneficial in treatment of experimental models of sepsis, might therefore be useful to treat sepsis syndrome in humans.

AB - Objectives: The aim of this research was to investigate endogenous concentrations and anti-cytokine effects of the anti-inflammatory peptide α- melanocyte stimulating hormone (α-MSH) in patients with systemic inflammation. The objectives were to determine the following: changes over time of plasma α-MSH and relationship with patient outcome, correlation between plasma α-MSH and tumor necrosis factor (TNF)-α plasma concentration and production in whole blood samples, and influences of α-MSH on production of TNF-α and interleukin (IL)-1β in whole blood samples stimulated with lipopolysaccharide (LPS). Design: Prospective, nonrandomized, clinical study. Setting: Intensive care unit of a university hospital. Patients: A total of 21 patients with sepsis syndrome/septic shock and an equal number of healthy volunteers. Interventions: Circulating α-MSH and TNF-α concentrations and TNF-α production in supernatants of LPS (1 ng/mL)-stimulated whole blood were measured repeatedly. To determine whether α-MSH can modulate production of TNF-α and IL-1 β, these cytokines were measured in whole blood samples stimulated with LPS (1 ng/mL) in the presence or absence of concentrations of the peptide. Measurements and Main Results: Plasma α-MSH was low in early samples and gradually increased in patients who recovered but not in those who died. There was a negative correlation between plasma concentrations of α-MSH and TNF-α. In blood samples taken at early phases of sepsis syndrome, production of TNF-α was reduced relative to control values; such production increased in patients who recovered but not in those who died. Addition of α-MSH to LPS-stimulated whole blood samples inhibited production of TNF-α and IL-1β in a concentration-dependent manner. Conclusions: In patients with systemic inflammation, there are substantial changes over time in plasma concentrations of α-MSH that are reduced in early phases of the disease. Reduction of this endogenous modulator of inflammation could be detrimental to the host. Addition of α-MSH to LPS-stimulated blood samples reduces production of cytokines involved in development of septic syndrome. This inhibition by α-MSH, a peptide that is beneficial in treatment of experimental models of sepsis, might therefore be useful to treat sepsis syndrome in humans.

KW - α-melanocyte stimulating hormone

KW - Cytokine production

KW - Interleukin-1

KW - Lipopolysaccharide

KW - Sepsis syndrome

KW - Septic shock

KW - Systemic inflammation

KW - Tumor necrosis factor-α

KW - Whole blood

UR - http://www.scopus.com/inward/record.url?scp=0034112590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034112590&partnerID=8YFLogxK

M3 - Article

C2 - 10834686

AN - SCOPUS:0034112590

VL - 28

SP - 1403

EP - 1407

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 5

ER -